Millis Oration | Dr Daniel Timms, BiVACOR
Wednesday 30 October | 9:30am - 10:00am
The Millis Oration is named in honour of Emeritus Professor Nancy Millis's contribution to the industry and is a focal point of the annual industry gathering, appropriately named after this pioneer of Australia’s biotechnology industry. It is held annually at the conference together with continuous support from CSL.
Keynote speaker Dr Daniel Timms, Founder & Chief Technical Officer, BiVACOR
Sponsored by
Keynote | Philipp Ernst, PsiQuantum
Wednesday 30 October | 10:00am - 10:30am
Fault tolerant quantum computing: Hardware, algorithms and their applications in biotech
Quantum computers hold the promise of revolutionizing fields from quantum chemistry to fluid dynamics. However, current noisy quantum computers are plagued by errors that limit their usefulness. This talk will provide a brief overview of the emerging field of fault-tolerant quantum computing (FTQC) which has the ability to correct errors, provide larger number of quantum gates, enabling more complex quantum algorithms, and finally deliver reliable results for useful, real-world applications.
We will delve into our photon-based approach to fault tolerance and will share the roadmap to delivering the world’s first utility-scale quantum computer, emphasising the advancements in photonics. Understanding these hardware developments is essential for anticipating the practical implementation of quantum algorithms for useful applications in biotech.
We'll then discuss how this technology unlocks the true potential of quantum algorithms applied to quantum chemistry problems and their relevance in biotech. We will cover algorithmic approaches for use-cases in quantum chemistry in precisely simulating molecular structures and reactions and how to address this in the context of large biomolecules. Finally, we'll address the future directions for bringing this transformative technology to the market.
Keynote speaker Philipp Ernst, Vice President of Quantum Solutions & Business Development, PsiQuantum
Keynote | Michael Hund, EB Research Partnerships
Wednesday 30 October | 9:30am - 10:00am
Venture into Cures- How patient foundations, Biotech, and Academia can unite via innovative business models to accelerate treatments and cures
Founded by a dedicated group of families set out to save their children's lives and Jill and Eddie Vedder of Pearl Jam, EB Research Partnership (EBRP) has the ambitious goal of curing the life-threatening rare skin disease Epidermolysis Bullosa (EB) by 2030 and in the process pioneering an innovative model for curing disease. As the largest global nonprofit dedicated to curing EB, EBRP has made remarkable progress: raising over $60 million to fund more than 140 global scientific projects and companies, growing the clinical trial landscape from 2 to more than 40 clinical trials, and achieving the first two FDA approved treatments in 2023. Their award-winning venture philanthropy and business model has garnered leadership recognition from Harvard Business School, Yale University, MIT, Stanford University, Rolling Stone, and Forbes. Learn how EBRP's innovative model can scale to bring together the nonprofit, biotech, academic, and regulatory industries to put speed into treating and curing diseases.
Keynote speaker Michael Hund, Global Chief Executive Officer, EB Research Partnerships
Keynote | Robert Marino, Qubit Pharmaceuticals
Friday 1 November | 3:00pm - 3:30pm
Further details to be confirmed.
Keynote speaker Robert Marino, Chief Executive Officer, Qubit Pharmaceuticals
Early-Stage Innovation Forum
Wednesday 30 October | 2:00pm - 5:40pm
Discover up to 15 emerging technologies at the Early-Stage Innovation Forum which enables early-stage projects and technologies from research institutes, universities, hospitals and pre-series A companies in the area of human therapeutics and enabling technologies to pitch to a panel of industry experts, corporate VCs and early-stage investors to continue their commercialisation journey.
See here for more information.
